A Study Evaluating MM-310 in Patients With Solid Tumors

Conditions:   Solid Tumors;   Urothelial Carcinoma;   Gastric Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Ovarian Cancer;   Pancreatic Ductal Adenocarcinoma;   Prostate Adenocarcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Triple Negative Breast Cancer;   Endometrial Carcinoma;   Soft Tissue Sarcoma
Intervention:   Drug: MM-310
Sponsor:   Merrimack Pharmaceuticals
Not yet recruiting - verified March 2017

http://ift.tt/2n78Vna